Truliant Porous Knee System Launches Reports Exactech

Truliant Porous Knee System Full Launch

Exactech, a developer and producer of innovative implants, instrumentation and smart technologies for joint replacement surgery, today announced the expansion of its Truliant® Total Knee System with a new porous-coated implant option.

Full launch of the Truliant Porous Knee System is welcome news for surgeons who are interested in a non-cemented approach. It enhances the award-winning knee system and is designed for strength and stability for patients, and efficiency for surgeons and staff in the operating room.

“Exactech’s Truliant Porous Knee system embodies state-of-the-art technology, manufacturing and instrumentation allowing surgeons to confidently address our ever-changing patient populations,” said James B. Duke, MD, of the Orthopaedic Institute in Ocala, Fla. “I believe surgeons looking to maximize longevity, performance and durability in their implants will want to utilize Exactech’s Truliant Porous Knee technology to best handle surgical challenges and patient expectations.”

The Truliant Porous Knee enhances the company’s advanced material science platform with a solution that is designed to mimic the trabecular nature of cancellous bone with optimal pore size and porosity. The porous structures integrated into the implant design are designed to facilitate a durable bonding surface to allow for immediate and long-term biological fixation. Peripheral pegs allow for stable initial fixation while the channeled keel is designed with flutes to increase bony-implant engagement for increased stability and resistance to micromotion.

The Truliant Porous Knee seamlessly integrates with the system’s ergonomically designed mechanical instrumentation and the ExactechGPS® TKA Pro application for a guided, personalized experience. The Truliant Total Knee System includes cruciate-retaining and posterior-stabilized implants, as well as constrained insert options, and integrates with a fully comprehensive revision system that offers metaphyseal cones, stems, tibial augments and offsets.

SourceExactech

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”